Laurus Labs Limited (BOM:540222)

India flag India · Delayed Price · Currency is INR
1,012.65
-5.55 (-0.55%)
At close: Dec 4, 2025
73.56%
Market Cap 547.11B
Revenue (ttm) 63.58B
Net Income (ttm) 6.84B
Shares Out n/a
EPS (ttm) 12.67
PE Ratio 79.99
Forward PE 66.53
Dividend 1.60 (0.16%)
Ex-Dividend Date Oct 31, 2025
Volume 45,375
Average Volume 72,869
Open 1,015.35
Previous Close 1,018.20
Day's Range 1,001.25 - 1,020.00
52-Week Range 504.30 - 1,040.00
Beta n/a
RSI 64.80
Earnings Date Oct 28, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2005
Employees 6,167
Stock Exchange Bombay Stock Exchange
Ticker Symbol 540222
Full Company Profile

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.

Financial Statements

News

There is no news available yet.